Rodent models of complement activation-related pseudoallergy: Inducers, symptoms, inhibitors and reaction mechanisms by Dézsi, László et al.
Eur. J. Nanomed. 2015; 7(1): 15–25
*Corresponding author: László Dézsi, Nanomedicine Research and 
Education Center, Semmelweis University, Budapest, Hungary, 
E-mail: dezsi.laszlo@med.semmelweis-univ.hu
László Rosivall: Department of Pathophysiology, Semmelweis 
University, Budapest, Hungary; and MTA-SE Pediatrics and 
Nephrology Research Group, Budapest, Hungary
Péter Hamar and Gábor Szénási: Department of Pathophysiology, 
Semmelweis University, Budapest, Hungary
János Szebeni: Nanomedicine Research and Education Center, 
Semmelweis University, Budapest, Hungary; Seroscience 
Ltd., Budapest, Hungary; and Faculty of Health, Department of 
Nanobiotechnology and Regenerative Medicine, Miskolc University, 
Miskolc, Hungary
Mini Review
László Dézsi*, László Rosivall, Péter Hamar, János Szebeni and Gábor Szénási
Rodent models of complement activation-related 
pseudoallergy: Inducers, symptoms, inhibitors 
and reaction mechanisms
Abstract: Complement activation-related pseudoallergy 
(CARPA) is a hypersensitivity reaction to intravenous 
administration of nanoparticle-containing medicines 
(nanomedicines). This review focuses on CARPA in rodent 
models: rats, mice, guinea pigs and rabbits. Information 
on all aspects of hypersensitivity reactions caused by 
known complement activators (zymosan, cobra venom 
factor) and different nanomedicines (liposomes, other 
drug carrier nanocarriers) in these species has been com-
piled and analyzed, trying to highlight the similarities and 
differences. What is most common in all species’ reactions 
to i.v. complement activators, liposomes and other nano-
particles is a dose-dependent hemodynamic and cardio-
pulmonary disturbance manifested in acute, reversible 
rise or fall of blood pressure and respiratory distress that 
can lead to shock. Other symptoms include heart rate 
changes, leukopenia followed by leukocytosis, thrombo-
cytopenia, hemoconcentration due to fluid extravasation 
(rise of hematocrit) and rise of plasma thromboxane B2. 
The results of a recent rat study are detailed, which show 
that rats are 2–3 orders of magnitude less sensitive to lipo-
some-induced CARPA than pigs or hypersensitive humans. 
It is concluded that CARPA can be studied in rodent mod-
els, but they do not necessarily mimic the human reac-
tions in terms of symptom spectrum and sensitivity.
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Introduction
Complement activation-related pseudoallergy (CARPA) is 
a hypersensitivity reaction to intravenous administration 
of nanoparticle-containing medicines (nanomedicines) 
in patients with occasionally serious consequences (1–4). 
The details of CARPA and its mechanisms are described in 
other chapters of this Special Issue. New nanomedicines 
should be tested in animals prior to human administra-
tion in order to avoid toxicity, including CARPA. Currently 
the porcine model of CARPA is the best to predict poten-
tial safety concerns of nanomedicines as the pig is highly 
sensitive to i.v. treatment with liposomes and other nano-
particles, as the resulting physiological changes can be 
extrapolated to humans with high certainty (5). However, 
new, less expensive models are also needed to advance 
the testing of nanomedicine-induced CARPA. Comple-
ment (C) activation can be easily tested in vitro, which is 
an inexpensive and rapid evaluation of potential safety 
risk (6, 7). Such in vitro tests can be tailored to fulfill 
species specificity requirements. However, the problem 
with in vitro-based systems is that the effector arm of 
immune response, most importantly the cardiovascu-
lar system, is not present (8). Therefore, reliable predic-
tion of immunotoxicity requires a battery of tests which 
includes both in vitro and in vivo models (9). Rodents are 
especially suitable for this purpose as huge amount of 
information is available concerning the pathophysiology 
of C activation in rodent species. However, rodents seem 
to be much less sensitive to nanomedicines than pigs 
(10, 11). The aim of the current review is to summarize 
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the available information on CARPA in rodents to get an 
insight into various C activation mechanisms elicited by 
nanomedicines that may be present in various rodent 
species.
The CARPAgenic effects of CVF, 
zymosan and LPS in rodents and 
their modulation with complement 
antagonists
Cobra venom factor (CVF) is a rapid activator of the com-
plement system, and intravenous treatment of rodents 
with CVF is a model of acute respiratory distress syn-
drome, a severe illness due, in part, to C activation. Some 
of the physiological changes caused by CVF in the pres-
ence or absence of C inhibitors include the following 
observations. Pretreatment of anesthetized rats i.v. or p.o. 
with AcF-[OP(D-Cha)WR], a C5a receptor (C5aR) antago-
nist, markedly attenuated CVF-induced (4 IU/kg) drop in 
polymorphonuclear (PMN) cell count and the long-lasting 
hypotension, but it did not alter the transient increase in 
blood pressure. On the other hand, N(2)-[(2,2-dipheny-
lethoxy)acetyl]-L-arginine, a C3a receptor (C3aR) antago-
nist, caused neutropenia on its own, which was similar 
to that of caused by CVF. It also attenuated CVF-induced 
transient hypertension but did not alter hypotension. 
Inhibition of both C3 and C5 convertases by rosmarinic 
acid (12) inhibited all the above responses. The increase 
in pulmonary vascular permeability was inhibited most 
by the C5aR antagonist. Rosmarinic acid was less effec-
tive, and the C3a receptor antagonist was the least effec-
tive in this respect. All three antagonists diminished the 
increases in plasma TNFα levels that peaked at 60  min 
after CVF administration (13).
A part of endotoxin (LPS) shock can be attributed 
to C activation as plasma levels of both C3a and C5a are 
markedly elevated in LPS-treated rats (14). The underly-
ing physiological changes include systemic hypotension 
and increased hematocrit, along with decreases of the 
leukocyte (PMN), monocyte, and platelet counts. Prior 
administration of a rat anti-C5a antibody failed to alter 
the hematologic changes and pulmonary edema caused 
by LPS, while the decrease in mean arterial pressure and 
the increase of hematocrit was partly prevented.
Zymosan is a ligand found on the surface of fungi, 
like yeast, and it is widely used to activate the alterna-
tive pathway of complement. It is a glucan with repeat-
ing glucose units connected by β-1,3-glycosidic linkages, 
which activates nuclear factor-κB (NF-κB) signaling 
in resident macrophages via Toll-like receptors (15). 
Damas et  al. performed a series of studies to explore 
the hemodynamic, pulmonary and hematologic effects 
of zymosan in rats, and reported the following changes 
(16–21). Intravenous treatment with zymosan reduced 
serum C hemolytic activity and caused leukopenia, 
thrombocytopenia, as well as decreased blood pressure 
and increased hematocrit as a result of extravasation 
of extracellular fluid in various vascular beds (16–21). 
Most importantly, zymosan increased right ventricular 
systolic pressure and respiratory rate (18), which is also 
a key finding in pigs after liposome administration (22). 
WEB 2086, a PAF antagonist, prevented the decreases in 
blood pressure and right ventricular systolic pressure, 
while indomethacin decreased the tachypnea and pul-
monary hypertension but enhanced the drop in blood 
pressure and right ventricular systolic pressure. The 
vascular permeability change in the lung was abolished 
by indomethacin, and no plasma extravasation was 
found in rats made leukopenic by rabbit anti-neutrophil 
serum. On the other hand, WEB 2086, the antihistamine, 
mepyramine or the non-selective serotonin antagonist, 
methysergide did not affect the vascular permeability 
response to zymosan in the lung. The zymosan-induced 
paw edema was prevented by pretreatment with the 
histamine H2 receptor antagonists, cimetidine and 
metiamide (19).
CARPA in pregnancy
The potential C activation-related harmful effects of 
nanomedicines can be even more serious in pregnancy, 
as sustained C activation is suspected to contribute to 
the development of gestational complications and preec-
lampsia (23, 24). Hypertension was induced in pregnant 
rats using the reduced uterine perfusion pressure (RUPP) 
model, and the animals were treated daily with the C5a 
receptor antagonist (C5aRA), PMX51 (acetyl-F-[Orn-P-
(D-Cha)-WR]), the C3a receptor antagonist (C3aRA), 
SB290157 (N2-[(2,2-diphenylethoxy) acetyl]-L-arginine) on 
gestational days 14–18. Both C3aRA and C5aRA par-
tially reversed hypertension on gestational day 19, while 
only the C5aRA lowered tachycardia and attenuated the 
impaired endothelium-dependent relaxation in the mes-
enteric artery (25). However, neither antagonist altered 
the decrease in plasma VEGF concentration, fetal retarda-
tion, but the C5aRA decreased the number of circulating 
neutrophils.
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Characteristics of liposome-induced 
CARPA in rats
The syndrome called later as CARPA was first demon-
strated in conscious rats by Rabinovici et  al. (1989), 
who studied the hemodynamic, hematologic and blood 
chemistry effects of liposome-encapsulated hemoglobin 
(LEH), a potential red blood cell substitute (26). Intrave-
nous injection of LEH induced a transient, but relatively 
long lasting ( < 120 min) hypertension and tachycardia 
that was accompanied by increases in hematocrit and 
white blood cell count, while platelet count decreased. 
Plasma thromboxane B2 (TXB2, the stable metabolite of 
TXA2) levels increased in inverse correlation with platelet 
count. Injection of the hemoglobin-free liposome vehicle 
caused hypotension and tachycardia, increased hemato-
crit, white blood cell count and plasma TXB2 levels but 
decreased platelet count (26, 27). In a subsequent study 
LEH was prepared using synthetic distearoyl phosphati-
dylcholine instead of hydrogenated soy lecithin. This 
change in formulation reduced the effects on heart rate 
and plasma TXB2 levels, while administration of lyophi-
lized LEH had no detectable hemodynamic, biochemical 
or hematologic effects (27, 28). These results established 
that the size and compositions of liposomes are key modi-
fiers of the hemodynamic and hematologic changes. The 
same authors also showed that pretreatment of rats with 
BN 50739, a platelet-activating factor (PAF) blocker pre-
vented the LEH-induced CARPA, suggesting that PAF is a 
key mediator of CARPA in rats (29).
Treatment with LEH and, to a lesser extent, hemo-
globin-free liposomes reduced plasma hemolytic C activity 
within a few minutes that came together with a reciprocal 
increase of plasma TXB2 levels in rats (30). In an attempt to 
explore the mechanism of C activation LEH was incubated 
in rat serum in the presence of EGTA/Mg++, which inhibits 
C activation via the classical pathway, or the serum was 
preheated to 50°C, which inhibits C activation via the 
alternative pathway. Since heating alone prevented C con-
sumption by LEH, it was concluded that LEH activated the 
alternative pathway (30). Furthermore, administration of 
soluble C receptor type 1 (sCR1), or C depletion using cobra 
venom (CVF) factor prevented the LEH-induced increase 
in plasma TXB2 levels. These results established a causal 
relationship between LEH-induced C activation and the 
release of TXB2 (31). In a later study it was revealed in con-
scious rats that treatment with liposome vesicles contain-
ing anionic phospholipid-methoxypolyethylene glycol 
(mPEG) conjugates decreased serum hemolytic C activity 
and increased plasma TXB2 levels, while the nonionic, 
methylated phospholipid-mPEG was free of such effects. 
Therefore, C activation was due to the zwitterionic phos-
pholipid head-groups that should be avoided in order to 
produce safer vesicles for site-specific drug delivery (32).
Another research group packed contrast agents 
in liposomes of various lipid compositions in order to 
prevent glomerular filtration of the contrast agents, and 
thereby lengthening their circulation time. As to the high 
dose of contrast agents to be administered, the amount of 
liposomes was also high. Not surprisingly 300 mg/kg i.v. 
hydrogenated soy phosphatidylcholine (HSPC) or 1,2-dis-
tearoyl-sn-glycero-3-phosphocholine (DSPC) induced 
drastic hypotension, decreased total peripheral resistance 
(TPR) and cardiac contractility (33). On the other hand, soy 
phosphatidylcholine (SPC) or the addition of cholesterol 
to DSPC reduced the hemodynamic effects of liposomes at 
the same dose. However, C activation parameters were not 
followed. In a subsequent study liposomes were injected 
i.v. in either maleic acid/NaOH, or Na2-EDTA (pH 6.65), or 
Tris-HCl buffer (pH 7.33) and also contained 300 mg/kg 
iopromide at a 1 to 1 lipid-to-drug ratio. The acidic prepa-
ration induced hypotension, decreased TPR and cardiac 
contractility, while the buffered preparation was much less 
effective. Acetylsalicylic acid prevented the hemodynamic 
effects (34). The authors concluded that the size, elec-
tric charge, and composition of liposomes were of major 
importance to elicit cardiovascular responses (34, 35).
In our laboratory we have applied the rat model of 
CARPA to investigate the immunological and hemody-
namic responses to intravenous (i.v.) bolus injections of 
liposomes differing in surface properties. Systemic arte-
rial blood pressure (SAP) and heart rate (HR) were con-
tinuously recorded in anesthetized male Wistar rats, and 
blood samples were taken to measure blood cell count 
and plasma TXB2 levels, as well as to determine total C 
activation using the classical C hemolytic (CH50) assay. 
The small unilamellar vesicles used in these studies, 
i.e., commercial Ambisome and a synthetic saturated PC 
(DPPC) and cholesterol-containing PEGylated liposome 
formulation wherein 2K-PEG is conjugated to cholesterol 
(Chol-PEG), had nearly identical size and polydispersity, 
but had very different surface properties that represented 
two frequently applied surface modification. Namely, 
AmBisome is a surface conjugate-free, highly anionic 
(negatively charged) liposome, while Chol-PEG liposomes 
are neutral, surface-stabilized stealth vesicles (Table 1). 
To induce CARPA, zymosan was utilized for direct C acti-
vation, while AmBisome and 2K-PEG-Chol (Chol-PEG), as 
mentioned above, served as liposomal C activators.
We have measured and compared the hemody-
namic and hematologic effects of these liposomes in 
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Table 1: Characteristics of liposomes applied in the study by Dézsi et al. (11), reproduced with permission.
Name Character Lipid composition Mole ratios Size, nm PDI Zeta potential, mV
AmBisome Anionic, no PEG HSPC/Chol/DSPG/Vit-E/Amph-B 49:23:18:0.3:9 98 0.12 –53.5
Chol-PEG Neutral-PEGylated DPPC/DSPE/Chol/2k-PEG-Chol 62:5:28:5 97 0.05 0.49
comparison with those caused by zymosan that served as 
positive control. The effects of zymosan administration at 
10 mg/kg i.v. are shown in Figure 1. A gradual decrease in 
SAP by 40% after 10 min (Figure 1A) could be observed, 
while HR (Figure 1B) did not change. We have also seen 
significant leukopenia by 50% at 5 min that was restored 
by 30 min (Figure 1C), which was associated with signifi-
cant thrombocytopenia by 30% after 1  min (Figure 1D). 
There was a severe reduction (by 60%) in hemolytic activ-
ity (Figure 1E), while plasma TXB2 exhibited significant, 
4-fold rise (Figure 1F).
AmBisome, calculated on its phospholipid 
(PL) content, was applied to rats at 22  mg PL/kg i.v. 
Administration of this lipid vesicle lead to a gradual 
decrease in SAP by 40% after 5 min (Figure 2A), while no 
change in HR (Figure 1B) was found. However, significant 
initial leukopenia by 50% at 5 min, switching to leukocy-
tosis by 10 min (Figure 2C) could be observed. This change 
paralleled the thrombocytopenia by 60% after 3–5  min 
(Figure  2D). At this high dose, we have seen a reduc-
tion in hemolytic activity by 40% (Figure 2E), however, 
plasma TXB2 rose only minimally (Figure 2F). Except for 
somewhat different hematologic (Figure 2C, D) and less 
TXB2 (Figure 2F) changes, the effect of 22 mgPL/kg AmBi-
some was essentially identical to that seen with10 mg/kg 
zymosan.
Figure 1: Physiological changes in rats injected with 10 mg/kg i.v. zymosan. Dézsi et al. (11), reproduced with permission. Values shown are 
Mean±SE (n = 8). The curves were constructed from the 0, 1, 3, 5, 10 and 30 min readings of SAP and HR after injection, as well as of other 
parameters measured from blood samples taken at the same time points. *, **, ***: p < 0.05, 0.01, 0.001 vs. the time 0 value.
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Zymosan, being a well-known C activator, the practi-
cal identities of the measured physiological effects and 
C activation by AmBisome and zymosan provides strong 
support for C activation underlying the observed hemody-
namic and hematologic changes.
Finally, the efficacy of the two types of liposomes 
with different surface characteristics was compared. Chol-
PEG liposomes at the dose of 60 mg PL/kg i.v. caused no 
changes in the measured parameters. Then the effects of 
a 5-fold higher dose (300 mg PL/kg Chol-PEG) were tested 
that also resulted only in minor changes. There was rela-
tively small, although significant decrease in SAP (by 
16%), while HR did not change. In parallel, we have found 
moderate leukopenia (but no leukocytosis), as well as 
thrombocytopenia (both 30%). A slight decrease in hemo-
lytic activity and a small rise in plasma TXB2 could also 
be observed. Thus, Chol-PEG liposomes turned out to be 
substantially less effective C activators in rats compared 
with AmBisome or zymosan.
This study confirmed previous claims that rats are 
less sensitive to liposome-induced reactions than pigs. 
For example, the effective AmBisome dose to induce a 
similar drop in SAP was 2200-fold higher in rats than in 
pigs, since 0.01 mgPL/kg i.v. was already effective in pigs. 
Another notion is that there could be huge differences 
between test agents of similar kind based on their physi-
cal characteristics. These figures provide strong evidence 
that the rat is not a sensitive model for immune toxicity 
screening or quantitative evaluation of the risk of CARPA. 
However, because the physiological changes in rats are 
essentially the same as those seen in pigs and humans, 
rats still provide a good model to study the reaction mech-
anisms of CARPA.
Effects of complement components 
C3a and C5a in the guinea pig
Complement C3a and C5a have distinct hemodynamic 
effects. Administration of porcine C5a or C5a des-Arg 
caused an immediate and short lived fall in blood pressure 
Figure 2: Physiological changes in rats injected with 22 mg PL/kg i.v. AmBisome (n = 8). Dézsi et al. (11), reproduced with permission. 
Similar experiments to that of Figure 1.
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followed by a longer hypertensive response lasting for a 
few minutes in anesthetized guinea-pigs. Only the hyper-
tensive effect was attenuated upon repeated administra-
tion, i.e., showed tachyphylaxis (36). Bronchoconstriction 
followed the same time-course as hypotension, but the 
reaction was also tachyphylaxic (36). The hypertensive 
effect was similarly, but only partly reduced by pretreat-
ment with histamine or alpha-adrenoceptor blockers, sug-
gesting that C5a caused catecholamine liberation through 
the release of histamine. The second, hypertensive phase 
of the C5a effect is specific for the guinea pig as C5a 
causes mainly hypotension in other species. Administra-
tion of C5a des-Arg induced hypotension that lasted for 
more than 10 min, and was prevented by indomethacin 
pretreatment. Later studies extended the above findings 
by demonstrating that indomethacin, the thromboxane 
synthetase inhibitor U-63557A and the thromboxane 
receptor antagonist SQ 29,548 all attenuated, but the LTD4 
antagonist L-649,923 failed to alter the C5a or C5a des-
Arg-induced hypertension in anesthetized guinea-pigs. 
In summary, the tachyphylactic histamine and catecho-
lamine release and the consequent hypertensive response 
induced by C5a was mediated by thromboxane. Contrary 
to the above findings, pyrilamine, a H1 antagonist did not 
alter, but phentolamine, an alpha-adrenergic antagonist 
inhibited the hypertensive effect. Treatment with C5a also 
decreased PMN and platelet counts. The C5a or C5a des-
Arg-induced blood pressure rise was diminished after 
depleting the animals’ platelets and white blood cells, 
while depleting the circulating PMN only had similar 
effects (37, 38).
The pulmonary response in anesthetized guinea-pigs 
to intravenous recombinant human C5a (rhC5a) was a 
reduction in dynamic lung compliance and an increase 
in pulmonary resistance. Similar to previous studies (39), 
bronchoconstriction followed the same time-course as 
hypotension, and it was also tachyphylaxic. Broncho-
constriction was not altered by pyrilamine despite an 
increase in plasma histamine levels. SQ 29,548, a selec-
tive thromboxane antagonist decreased the peak response 
only, while the superoxide dismutase and TXA2 inhibitor 
U-63557A altered the time course of the bronchoconstric-
tor response (39). The time course and magnitude of bron-
choconstriction was not affected by selective depletion of 
PMN, platelets or both. However, pyrilamine inhibited the 
bronchoconstriction after depletion of both circulating 
PMN and platelets (38). Thus, similar to the hypertensive 
response, an increased pulmonary resistance due to bron-
choconstriction was most likely mediated by the effect of 
thromboxane, while granulocytes and platelets were less 
important.
Similarly to C5a, treatment with C3a-peptide (the last 
21 amino acids of guinea pig C3a) caused a huge increase 
in pulmonary resistance and a decrease in dynamic 
lung compliance in guinea pigs (40). C3a-peptide also 
induced a transient systemic hypotension, followed by 
a longer hypertension lasting for about 5 min, and then 
blood pressure decreased for an additional 10–15 min. 
All these responses were absent in the C3a receptor-defi-
cient (C3aR-) guinea pigs. Administration of recombinant 
human C5a (rhC5a) evoked almost the same responses to 
C3a-peptide with similar magnitude and time course in 
normal and C3aR- guinea pigs. The ovalbumine-induced 
increase in pulmonary resistance and decrease in dynamic 
lung compliance was slightly delayed but was not attenu-
ated in C3aR- vs. normal guinea pigs. On the other hand, 
the triphasic blood pressure response was altered in C3aR- 
guinea pigs in such a way that the hypertensive effect was 
aggravated and delayed and the late hypotensive effect 
was attenuated, suggesting a minor role of C3aR in the 
anaphylactic response in guinea pigs (40).
Effects of complement components 
C3a and C5a in the rat
Treatment with C5a desArg (5 μg/rat) decreased mean 
arterial pressure and PMN, monocyte and platelet counts 
but did not alter hematocrit in rats (14). Administration of 
rhC5a induced an almost immediate hypotension lasting 
for more than 2 h, and resulted in a shorter,  < 30  min 
drop of circulating PMN cell count in rats (41). On the 
other hand, treatment with rhC3a caused a rapid, dose-
dependent hypertension that lasted for a maximum of 
5 min. The hypertensive effect was slightly potentiated by 
pretreatment with carboxypeptidase N inhibitor but was 
abolished by indomethacin. Administration of rhC3a ele-
vated PMN cell count with a delay of about 90 min at low 
doses, while at high doses it similarly elevated PMN cell 
count that was preceded by a small neutropenia lasting 
for about 60 min, but this early response failed to reach 
the level of statistical significance. Pretreatment with car-
boxypeptidase N inhibitor abolished the delayed increase 
in PMN cell count that was caused by the low dose of 
rhC3a, but elicited an early and small neutropenia that 
was similar to that induced by the high dose of rhC3a (41).
One of two short peptide C5a agonist bound to C5aR 
on both PMN and macrophages while the other had affin-
ity only for the macrophage C5aR. As a consequence, 
both C5a agonists decreased blood pressure of anaes-
thetized rats, while only the agonist with affinity for the 
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granulocyte C5aR caused neutropenia (8). These results 
gave an insight into the mechanism of the various effects 
of C activation, and raise the possibility of selectively 
altering various consequences of CARPA.
There are only a few studies on the effects of C in the 
pulmonary vasculature in rats. Therefore it is an impor-
tant observation that the infusion of the 21-carboxy-
terminal peptide of C3a (C3a57-77) caused an immediate 
pulmonary vasoconstriction lasting for 10 min in isolated, 
crystalloid buffer-perfused rat lungs. There was a parallel 
increase in lung-effluent TXB2 level, which was directly 
responsible for the pulmonary vasoconstriction as both 
indomethacin and the thromboxane synthetase inhibi-
tors CGS 13080 and U63,357 inhibited the pulmonary arte-
rial pressor response (42). These results call the attention 
to the fact that the rat lung can be a direct target organ 
of CARPA despite the absence of pulmonary intravascu-
lar macrophages (PIM cells), which cells seem to have a 
pivotal role in making the lungs the primary responder 
organ in the highly CARPA sensitive pigs (11).
Effects of complement components 
C3a and C5a in the rabbit, hamster 
and mouse
In anesthetized rabbits treatment with C5a induced a 
systemic hypotension lasting for about 10 min, a fall in 
white blood cell count, and an increase in plasma his-
tamine, PGE2, TXB2 and prostacyclin levels, while heart 
rate, cardiac contractility, hematocrit and platelet count 
did not change (43). PMN cells almost fully disappeared 
from the blood, while lymphocyte cell count decreased by 
about 50%. Central venous pressure increased in paral-
lel with hypotension. All effects remained the same upon 
repeated administration of C5a. Pretreatment with indo-
methacin abolished the hemodynamic and prostaglandin 
responses but leukopenia reappeared. In contrast, the 
H1-receptor antagonist pyrilamine, and the thromboxane 
synthetase inhibitor dazoxibene failed to alter the hemo-
dynamic responses, while the H2-receptor antagonist 
cimetidine attenuated the blood pressure drop and the 
elevations in plasma prostaglandin levels (43).
A detailed study evaluated leukopenia and subse-
quent leukocytosis activity of human C5a in a rabbits. 
Neutrophil, monocyte, eosinophil, and basophil counts all 
rapidly dropped upon intravenous treatment with human 
C5a, suggesting the C5a-activated leukocytes which 
become adherent, leading to sequestration, and depletion 
of cells from the circulation. However, C5a seem to mobi-
lize bone marrow causing a huge increase in monocyte, 
eosinophil, and basophil counts starting at 10–20  min 
after treatment. Indomethacin failed to alter the effects of 
C5a. Epinephrine, dexamethasone, lipopolysaccharide, 
and the prostanoid 15(S)-15-methyl PGF2α produced a dif-
ferent profile of leukocyte mobilization than that of C5a. It 
was hypothesized that C5a was directly responsible for the 
leukocitosis without the involvement of secondary media-
tors (44).
The hamster cheek pouch is a suitable model for 
studying the microvascular effects of C3a and C5a. Topical 
application of C3a (10 nM) caused local vasoconstriction, 
platelet aggregation, and increased vascular leakage of 
fluorescein-labeled dextran. Higher doses of C5a (20 or 
100 nM) had the same effects also resulted in accumula-
tion of PMN. Pretreatment with mepyramine, a histamine 
H1 receptor blocker partially inhibited the early phase (up 
to 5 min) of complement-induced extravasation, which 
was also partly due to recruitment of PMN (45).
Liposome-induced CARPA was rarely evaluated in 
mice in vivo but the result of a number of excellent in 
vitro tests have been published, among others a study by 
Banda et  al., showed that iron-containing nanoparticles 
can activate complement in mouse serum via the lectin 
and alternative pathways (46). A recent in vivo study has 
shown that intravenous treatment with a polyethoxylated 
castor oil-free, liposome-based paclitaxel formulation or 
paclitaxel-free liposomes caused hypersensitivity reac-
tions after treatment, including shortness of breath and 
dyspnea. The paclitaxel formulation induced pulmonary 
edema, and increased serum sC5b-9 and lung histamine, 
i.e., caused C activation (47). These results suggest that in 
mice also the lung seems to be the primary target organ 
similarly to pigs (22). The role of zymosan causing plasma 
extravasation was widely investigated in the zymosan-
induced peritoneal inflammation model in mice. Zymosan 
increased vascular permeability and caused peritoneal 
inflammation in Balb/c mice. The role of mast cells was 
found to be crucial in the zymosan-induced peritonitis, 
which was mediated via histamine receptors (48). Other 
authors have found that leukotriene C4 synthase (LTC4S) 
mediates an increased vascular permeability (49). These 
effects were lacking in mast cell-deficient WBB6F1 Balb/c 
mice and LTC4S-/- C57BL/6 mice (48, 49).
Although we consider the liposome-induced CARPA 
as a side-effect due to C activation, liposomes can activate 
PMN leukocytes that can lead to a therapeutic effect. In 
fact, empty liposomes were similarly effective to liposo-
mal amphotericin B in alleviating invasive pulmonary 
aspergillosis in a non-neutropenic murine model (50).
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Characteristic changes of in vivo observed parameters 
in various rodent models of CARPA are summarized in 
Table 2.
Conclusions
Although the effects of treatment with nanoparticle-con-
taining carrier systems and medicines have not been fully 
explored in all rodent species, the collective results une-
quivocally prove that all major characteristics of CARPA 
are present in rodents including respiratory, hemody-
namic and hematologic effects. The current information 
clearly shows that rodents represent appropriate models 
to study the reaction mechanisms of CARPA, as well as 
rodents are suitable for safety prediction of side effects 
of nanomedicines in humans, although at a much lower 
level of sensitivity.
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